Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells.

Cerchio R Jr, Marinaro C, Foo TK, Xia B, Chen S.

Melanoma Res. 2019 Dec 17. doi: 10.1097/CMR.0000000000000652. [Epub ahead of print]

PMID:
31855905
2.

Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance.

Bernard A, Chevrier S, Beltjens F, Dosset M, Viltard E, Lagrange A, Derangère V, Oudot A, Ghiringhelli F, Collin B, Apetoh L, Feron O, Chen S, Arnould L, Végran F, Boidot R.

Cancer Res. 2019 Dec 1;79(23):5958-5970. doi: 10.1158/0008-5472.CAN-19-0840. Epub 2019 Oct 14.

PMID:
31611309
3.

The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, in vitro and in vivo.

Khan AJ, LaCava S, Mehta M, Schiff D, Thandoni A, Jhawar S, Danish S, Haffty BG, Chen S.

Oncotarget. 2019 Apr 19;10(29):2824-2834. doi: 10.18632/oncotarget.26854. eCollection 2019 Apr 19.

4.

Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma.

Shah R, Singh SJ, Eddy K, Filipp FV, Chen S.

Cancer Res. 2019 Apr 15;79(8):1799-1809. doi: 10.1158/0008-5472.CAN-18-1500. Epub 2019 Apr 15.

5.

Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo.

Shin SS, Jeong BS, Wall BA, Li J, Shan NL, Wen Y, Goydos JS, Chen S.

Oncogenesis. 2018 Nov 14;7(11):86. doi: 10.1038/s41389-018-0098-7.

6.

Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2018;66(3):1213-1221. doi: 10.3233/JAD-180564.

7.

Frontiers in pigment cell and melanoma research.

Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF.

Pigment Cell Melanoma Res. 2018 Nov;31(6):728-735. doi: 10.1111/pcmr.12728. Epub 2018 Oct 3.

8.

Correction: Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.

Marciel MP, Khadka VS, Deng Y, Kilicaslan P, Pham A, Bertino P, Lee K, Chen S, Glibetic N, Hoffmann FW, Matter ML, Hoffmann PR.

Oncotarget. 2018 Jul 20;9(56):30937. doi: 10.18632/oncotarget.25857. eCollection 2018 Jul 20.

9.

Dipeptide Prodrugs of the Glutamate Modulator Riluzole.

Pelletier JC, Chen S, Bian H, Shah R, Smith GR, Wrobel JE, Reitz AB.

ACS Med Chem Lett. 2018 Jun 15;9(7):752-756. doi: 10.1021/acsmedchemlett.8b00189. eCollection 2018 Jul 12.

10.

Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.

Marciel MP, Khadka VS, Deng Y, Kilicaslan P, Pham A, Bertino P, Lee K, Chen S, Glibetic N, Hoffmann FW, Matter ML, Hoffmann PR.

Oncotarget. 2018 Feb 3;9(17):13407-13422. doi: 10.18632/oncotarget.24388. eCollection 2018 Mar 2. Erratum in: Oncotarget. 2018 Jul 20;9(56):30937. Deng, Youpeng [corrected to Deng, Youping].

11.

Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors.

Lopez-Tapia F, Brotherton-Pleiss C, Yue P, Murakami H, Costa Araujo AC, Reis Dos Santos B, Ichinotsubo E, Rabkin A, Shah R, Lantz M, Chen S, Tius MA, Turkson J.

ACS Med Chem Lett. 2018 Feb 16;9(3):250-255. doi: 10.1021/acsmedchemlett.7b00544. eCollection 2018 Mar 8.

12.

Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo.

Chen HC, Sierra J, Yu LJ, Cerchio R Jr, Wall BA, Goydos J, Chen S.

Oncotarget. 2017 Dec 23;9(5):5861-5875. doi: 10.18632/oncotarget.23637. eCollection 2018 Jan 19.

13.

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Mehnert JM, Silk AW, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS.

Pigment Cell Melanoma Res. 2018 Jul;31(4):534-540. doi: 10.1111/pcmr.12694. Epub 2018 Apr 10.

14.

Exosomes released by metabotropic glutamate receptor 1 (GRM1) expressing melanoma cells increase cell migration and invasiveness.

Isola AL, Eddy K, Zembrzuski K, Goydos JS, Chen S.

Oncotarget. 2017 Dec 19;9(1):1187-1199. doi: 10.18632/oncotarget.23455. eCollection 2018 Jan 2.

15.

Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS.

Expert Opin Ther Targets. 2018 Jan;22(1):9-17. doi: 10.1080/14728222.2018.1413091. Epub 2017 Dec 10. Review.

16.

Editorial: GPCRs and Cancer.

Chen S.

Front Genet. 2017 Oct 31;8:162. doi: 10.3389/fgene.2017.00162. eCollection 2017. No abstract available.

17.

Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells.

Dolfi SC, Medina DJ, Kareddula A, Paratala B, Rose A, Dhami J, Chen S, Ganesan S, Mackay G, Vazquez A, Hirshfield KM.

Oncotarget. 2017 Jul 4;8(27):44639-44653. doi: 10.18632/oncotarget.17961.

18.

Extracellular vesicles: important players in immune homeostasis.

Isola AL, Chen S.

Ann Transl Med. 2017 May;5(Suppl 1):S16. doi: 10.21037/atm.2017.03.76. No abstract available.

19.

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.

Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, Ganesan S.

Clin Cancer Res. 2017 Sep 15;23(18):5631-5638. doi: 10.1158/1078-0432.CCR-16-0758. Epub 2017 May 24.

20.

Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma.

Isola AL, Eddy K, Chen S.

Cancers (Basel). 2016 Dec 9;8(12). pii: E110. Review.

Supplemental Content

Loading ...
Support Center